ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3148

Peptidylarginine Deiminase 2 Is Required for Tumor Necrosis Factor Alpha Induced Citrullination and Arthritis, but Not Neutrophil Extracellular Trap Formation

Mandar Bawadekar1, Daeun Shim1, Ryan Rebernick1, Chloe Peyton1, Chad J. Johnson2, Thomas F. Warner3, Dres Damgaard4, Claus Henrik Nielsen5, Anthony P. Nicholas6, Ger JM Pruijn7, Jeniel E. Nett8 and Miriam A. Shelef1,9, 1Department of Medicine, Division of Rheumatology, University of Wisconsin-Madison, Madison, WI, 2Department of Medicine, University of Wisconsin-Madison, Madison, WI, 3Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, 4Institute for Inflammation Research, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, 5Danish Rheumatologic Biobank and DANBIO registry, Rigshospitalet, Glostrup, Gentofte and Herlev University Hospital, Copenhagen, Denmark, 6Neurology, University of Alabama at Birmingham and Birmingham VA Medical Center, Birmingham, AL, 7Biomolecular Chemistry, Institute for Molecules and Materials and Radboud Institute for Molecular Life Sciences, Radboud University, Nijmegen, Netherlands, 8Medicine and Medical Microbiology and Immunology, University of Wisconsin-Madison, Madison, WI, 9William S. Middleton Memorial Veterans Hospital, Madison, WI

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: animal models and tumor necrosis factor (TNF), citrullination, NETosis, PAD, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Wednesday, November 16, 2016

Title: Rheumatoid Arthritis – Animal Models II

Session Type: ACR Concurrent Abstract Session

Session Time: 9:00AM-10:30AM

Background/Purpose: The presence of anti-citrullinated protein antibodies in rheumatoid arthritis points to a potential role for citrullination in disease pathogenesis. Peptidylarginine deiminases (PADs) catalyze the conversion of peptidylarginine to peptidylcitrulline. PAD2 and PAD4 are expressed in immune cells, but it is not known if either of these PADs is required for the increased citrullination seen in inflammatory arthritis. Neutrophil extracellular traps (NETs) may be a source of citrullinated proteins in inflammation. PAD4 is critical for NETosis and inflammatory arthritis, but the role of PAD2 is unknown. Here we use mice with TNFα-induced arthritis, an inflammatory, destructive arthritis similar to rheumatoid arthritis, to determine if PAD2 and/or PAD4 are required for joint citrullination and if PAD2 is required for NETosis and inflammatory arthritis.

Methods: Joint lysates from wild type, TNFα overexpressing (TNF+), TNF+PAD4+/+, TNF+PAD4-/-, TNF+PAD2+/+, and TNF+PAD2-/- mice were assessed for citrullination by western blot using an anti-peptidylcitrulline antibody. PAD2 levels were determined by qPCR in PAD4+/+ and PAD4-/- spleens and by western blot in TNF+PAD4+/+ and TNF+PAD4-/- joints. NETs formed by LPS-stimulated PAD2+/+ and PAD2-/- neutrophils were detected by immunofluorescent staining with DAPI and anti-citrullinated histone H4 and quantified. Killing of Candida by PAD2+/+ and PAD2-/- neutrophils was determined by a modified XTT assay. In TNF+PAD2+/+ and TNF+PAD2-/- mice, bone marrow plasma cells were identified by flow cytometry, serum IgG detected by ELISA, and arthritis assessed by blinded clinical and pathological scoring.

Results: TNF+ ankles had increased citrullination compared to wild type. TNF+PAD2-/- ankles had less citrullination than TNF+PAD2+/+ ankles, but citrullination was not reduced in TNF+PAD4-/- compared to TNF+PAD4+/+ ankles. There was no compensatory increase in PAD2 in PAD4 deficient spleens or arthritic ankles. NETosis and killing of Candida were not reduced in PAD2-/- compared to PAD2+/+ neutrophils. Plasma cells, IgG, and arthritis were reduced in TNF+PAD2-/- compared to TNF+PAD2+/+ mice.

Conclusion: PAD2 contributes to TNFα-induced arthritis, plasma cell numbers, and IgG levels. Also, PAD2 is required for TNFα-induced joint citrullination, but not NETosis. In contrast, PAD4, which has been shown to be critical for NETosis, does not play a major role in TNFα-induced joint citrullination. Thus, NETs may not be the main source of citrullinated protein in arthritic mice.


Disclosure: M. Bawadekar, None; D. Shim, None; R. Rebernick, None; C. Peyton, None; C. J. Johnson, None; T. F. Warner, None; D. Damgaard, mAbSolution, 4; C. H. Nielsen, mAbSolution, 4; A. P. Nicholas, None; G. J. Pruijn, ModiQuest, 4; J. E. Nett, None; M. A. Shelef, None.

To cite this abstract in AMA style:

Bawadekar M, Shim D, Rebernick R, Peyton C, Johnson CJ, Warner TF, Damgaard D, Nielsen CH, Nicholas AP, Pruijn GJ, Nett JE, Shelef MA. Peptidylarginine Deiminase 2 Is Required for Tumor Necrosis Factor Alpha Induced Citrullination and Arthritis, but Not Neutrophil Extracellular Trap Formation [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/peptidylarginine-deiminase-2-is-required-for-tumor-necrosis-factor-alpha-induced-citrullination-and-arthritis-but-not-neutrophil-extracellular-trap-formation/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/peptidylarginine-deiminase-2-is-required-for-tumor-necrosis-factor-alpha-induced-citrullination-and-arthritis-but-not-neutrophil-extracellular-trap-formation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology